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In cattle (Bos taurus), the immunologically naïve calf receives immune factors, growth factors and 
nutrients from the dam via the colostrum. Colostral antibodies are primarily serum-derived and 
provide the calf with the broad-spectrum systemic immunity of the mother. There are a variety of 
commercially available products used to supplement or replace maternal colostrum. In addition to 
utilizing colostrum as the IgG source, there is an interest in using IgG from milk and serum as 
ingredients in colostrum replacement products. Immunoglobulins in milk are primarily derived 
from udder-localized plasma cells, which migrate from the intestinal mucosa at parturition and 
during lactation. We hypothesized that milk IgG would have lower levels of antibodies to systemic 
pathogens compared to colostrum and/or serum derived IgG however might contain higher levels 
of antibodies to mucosal and udder associated agents. We sampled serum (1-2hr post partum), 
colostrum (1-2hr post partum) and milk (day 5 post partum) from 24 post parturient dairy cows 
and heifers, measured total IgG (H+L) using a radial immunodiffusion assay (RID), and 
determined specific antibody units per gram of IgG for a variety of respiratory, gut and udder-
associated pathogens via indirect Enzyme-Linked Immunosorbant Assay (ELISA) (ie., BRSV, 
BHV-1, PI3, Streptococcus uberis, Staphylococcus aureus., E. coli F5 (K99), rotavirus and bovine 
coronavirus). We performed additional ELISAs to determine antigen specific values for IgG1 and 
IgG2 antibody subclasses for BRSV, rotavirus and S. uberis. Wilcoxon signed-rank tests with 
conservative Bonferroni correction, showed that antigen specific antibodies to BRSV (IgG H+L), 
PI3 (IgG H+L), E. coli F5 (K99) (IgG H+L), S. aureus (IgG H+L), rotavirus (IgG H+L and IgG1) 
and BCV (IgG H+L) are higher (P<.017) in the IgG in colostrum than the IgG in milk. In 
comparison to the serum, colostrum IgG is higher (P<.017), in BRSV (IgG H+L and IgG1), BHV1 
(IgG H+L), PI3 (IgG H+L), E. coli F5 (K99) (IgG H+L), S. uberis (IgG H+L), and rotavirus (IgG1) 
antibodies. Colostrum IgG also contains more specific antibody to S. uberis (IgG1) and BCV 
(H+L) than serum IgG. However, milk IgG contains more specific antibody to BRSV (IgG H+L 
and IgG1), BHV1 (IgG H+L), PI3 (IgG H+L), and rotavirus (IgG1) when compared to serum IgG 
(P<.017). Overall, colostrum derived IgG delivers more specific antibodies to most endemic 
pathogens compared to the IgG found in milk or serum. However, milk IgG, like that of colostrum, 
has higher amounts of specific IgG1 and delivers a similar spectrum of specific antibodies and 
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The beef and dairy industries are of significance to the Canadian agricultural economy, 
netting respectively $9.4 and $6.99 billion in farm cash receipts in 2019 alone. However, studies 
report calf morbidity in dairy herds as high as 34-35% (Urie et al., 2018; Waltner-Toews et al., 
1986), and in the United States, pre-weaned dairy calves have an average mortality rate of between 
5-11% (Beam et al., 2009; Urie et al., 2018; USDA APHIS | NAHMS Dairy Studies, 2007, 2014). 
These elevated rates of morbidity and mortality ultimately translate to reduced productivity, 
economic losses due to costs of therapies, reduced weight gain, and deaths (Rossini, 2004; Sivula 
et al., 1996; Stanton et al., 2012). The most common causes of morbidity and mortality in calves 
are neonatal calf diarrhea and bovine respiratory disease (BRD) (Donovan et al., 1998; Van 
Donkersgoed et al., 1993; Wells et al., 1996). Both are multifactorial diseases, classified as such 
because while the causative agents must be present for disease development, their presence alone 
is not sufficient to cause disease. In fact, most of these pathogens are environmentally ubiquitous 
and thus exposure for neonatal calves in livestock operations is guaranteed. 
In ruminants, the young are born almost agammaglobulinemic and the passive transfer of 
immunoglobulins from maternal colostrum is critical to the survival of the neonate in the first 
weeks until its own immune responses are protective (Gullickson et al., 1942). Failure of passive 
transfer of maternal immunity is the primary factor contributing to the mortality of pre-weaned 
calves and is, therefore, a major economic consideration for livestock producers (Windeyer et al., 
2014). Colostrum replacer products (CR) provide a practical way to improve passive transfer in 
calves, allowing producers to feed a known mass of IgG. However, the results of colostrum 
replacer trials have been inconsistent, with many products failing to provide the serum levels of 
IgG considered the minimum for successful passive transfer (reviewed in, Cabral et al., 2013; 
reviewed in, Godden & James, 2020). Additionally, depending upon the CR product, feeding the 
same IgG mass in maternal colostrum and CR formulations may not provide the same rates of 
passive transfer (Cabral et al., 2013; reviewed in, Godden & James, 2020).  
CR products may be derived from colostrum, milk whey, serum or a combination thereof. 
Variable success of CR products in achieving adequate passive transfer IgG levels may be partially 
due to differences in apparent efficiency of absorption (AEA) of immunoglobulin from colostrum, 
whey and serum-derived products compared to natural colostrum (reviewed in, Cabral et al., 2013). 
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There are a number of other potential reasons for poor performing CR products. Colostrum must 
go through a great deal of processing, including heat treatment and spray drying for use as a safe 
and shelf-stable product and that processing must be closely monitored to prevent damage to 
proteins and other components (Campbell et al., 2007; Thornsberry & Wood, 2011). Manufacturer 
instructions for reconstituting, feeding and feeding times must be closely observed. There is some 
evidence that high levels of other proteins in the colostrum product can competitively bind protein-
binding sites and channels, inhibiting the non-selective uptake of immunoglobulins and other 
immune factors (Besser & Osborn, 1993). Colostrum also likely contains factors that increase the 
rate of gut closure, effectively decreasing the window for passive transfer (Besser & Osborn, 
1993). 
Maternal colostrum is the most obvious source of Igs for CR products. Immunoglobulins 
found in colostrum are selectively transferred from the serum into the udder by receptor-mediated 
processes in the weeks leading up to parturition. These immunoglobulins provide systemic 
immunity and, through resecretion, mucosal immunity that is both broad-spectrum and 
environmentally relevant to the neonate (reviewed in, Hurley, 2003). While the ideal choice of 
immunoglobulin for CR formulations is therefore assumed to be colostrum, high quality maternal 
colostrum (MC) is expensive, in short supply, and even MC-derived CR products do not 
consistently perform as well as high quality maternal colostrum (reviewed in, Cabral et al., 2013).  
Serum is a potential source of immunoglobulins in CR products. Large volumes of serum 
are available as a by-product of the slaughterhouse industry. Serum contains a broad range of 
immunoglobulins, with the IgG1 and IgG2 subclasses of IgG represented equally. To date, studies 
investigating the performance of serum-derived CR products are mixed. If fed containing high 
enough IgG mass, serum-based products can provide neonates with adequate serum 
immunoglobulin levels to meet the standards for successful passive transfer of immunity 
(Arthington et al., 2000). However, the variable success of serum based CR products indicates that 
these products are not without functional and absorptive issues (reviewed in, Cabral et al., 2013; 
reviewed in, Godden & James, 2020). Most pertinent is that serum is composed of an equal ratio 
of IgG1 and IgG2 subclasses, while maternal colostrum contains primarily the IgG1 subclass and 
only IgG1 has been shown to have the capacity for re-secretion and thus protection at mucosal 
surfaces (Besser, McGuire, et al., 1988; Ellis et al., 2018). Additionally, serum products appear to 
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have reduced efficiency of absorption of immunoglobulins (Campbell et al., 2007; reviewed in, 
Godden et al., 2019; Thornsberry & Wood, 2011).  
Antibodies in milk, in contrast to both colostrum and serum, are assumed to be primarily 
derived locally in the udder, and potentially from cells that migrate from the intestinal mucosa 
during lactation, possibly providing the newborn calf preferentially with antibodies to agents 
associated with mucosal surfaces; particularly pathogens responsible for neonatal calf diarrhea 
(Besser, McGuire, et al., 1988; Butler et al., 1972, 1986; Sordillo & Nickerson, 1988). Dairy cows 
produce milk in excess of the nutritional needs of the calf, and the excess is regularly harvested 
and processed in large volumes in the dairy and cheese industries, leaving an excess of Ig-rich 
milk whey as a by-product. The spectrum of milk antibody types (IgG, IgA, IgM) and subclasses 
is similar to that of colostrum with a high proportion comprised of the IgG1 subclass (reviewed in, 
Larson, 1992; reviewed in, Tizard, 2018). Though the concentration of immunoglobulin in the 
milk is quite low, it can be concentrated. A number of naturally occurring enzymes and compounds 
including lactoferrin, lactoperoxidase and lysozyme are currently harvested from milk for the 
health and cosmetics industries. Additionally, hyperimmune milk from cows vaccinated to 
increase targeted antibody responses to rotavirus and cryptosporidium have been used to treat these 
infections in people (Mitra et al., 1995; Okhuysen et al., 1998). The similar IgG subclass ratio and 
the potential for greater proportions of some important specific immunoglobulins compared even 
to colostrum, suggests that milk IgG is an appropriate ingredient in colostrum replacer for calves. 
Milk derived immunoglobulin has been used in some countries including the USA for many 
decades as an ingredient in CR products (Mee et al., 1996), however its efficacy has not been 
studied or compared to other sources.  
Colostrum management programs on farms are a vital part of maintaining calf health and 
improving economic efficiencies. CR products can provide convenient, consistent nutrition and 
immune factors, and allow cattle operations to break the cycle of transmission of some common 
bovine pathogens. Currently, there are no studies addressing concerns that the specificity of 
immunoglobulins in milk whey or serum may differ from those of colostrum and the potential for 
those differences to impact the efficiency of the immunoglobulin of the IgG in colostrum 
replacement formulas. A more complete understanding of the antibody specificity of colostrum, 
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serum and milk could influence their use and potentially lead to improved colostrum management 
tools and improved calf health and performance outcomes.
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1. LITERATURE REVIEW 
1.1 Passive Immunity 
Passive immunity is defined as the transfer of specific antibodies or immunoglobulins from 
one individual to another to provide short-term protection against infection or disease. First 
demonstrated experimentally over 100 years ago to protect rabbits from lethal doses of cobra 
venom, passive immunization has since been utilized extensively to treat and prevent diseases in 
both animals and humans (Calmette, 1896; Eibl, 2008; Hsu & Safdar, 2011). The passive immunity 
provided through the transfer of immunoglobulins from mother to progeny (passive transfer of 
maternal immunity) offers immediate protection via environmentally relevant antibodies, 
developed in response to the antigenic challenges faced by the dam in the weeks leading up to 
parturition. The mechanism through which antibodies are passed to the young of a given species 
is variable. In mammals, protective immunoglobulin may be exchanged via the placenta, through 
the mammary gland secretions, or a combination of the two (reviewed in, Butler et al., 2015; Butler 
& Kehrli, 2005; Hurley, 2003). In contrast to mice and humans, that receive immunoglobulins in 
utero, many domestic animals receive most or all of their passive immunity via the placenta. In 
cattle (Bos taurus), and other ruminants, the placental structure completely prevents in utero 
transmission of immunoglobulin (Arthur et al., 1996; reviewed in, Butler et al., 2015; Hurley & 
Theil, 2011; Palmeira et al., 2012).  
Ruminants, therefore, are born almost agammaglobulinemic and are highly susceptible to 
infectious disease. Newborn ruminants receive all systemic passive immunity through the first post 
partum mammary secretion, the colostrum (Senger, 1997). Maternal Igs in the colostrum are 
ingested and absorbed across the lamina propria of the small intestine and move into the 
bloodstream during the first 24 hours following birth (Hurley & Theil, 2011; Palmeira et. al., 
2012).  
Passive immunization through the oral administration of exogenous immunoglobulins may 
also supplement local mucosal immunity in individuals incapable of systemic absorption of 
immunoglobulin (Besser, Gay, et al., 1988; Saif et al., 1983). Passive immunization via antibodies 
in milk diets has proven to be a particularly effective strategy for the protection of young livestock 
animals in the face of common enteric pathogen challenges, blocking the attachment of pathogens 
and promoting their excretion (Arthington et al., 2002; Berge et al., 2009, 2009; Jones et al., 1988; 
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Nagy, 1980; Parreño et al., 2004, 2010; Rousic et al., 2000; Saif & Fernandez, 1996). 
In calves, studies with radio-labelled immunoglobulins show no intestinal absorption of 
IgG1 from the milk, demonstrating endogenous production of IgG1 starting as early as 36h after 
birth (Devery et al., 1979). However, innate antibody production appears to be tied to passive 
transfer level. In calves with high serum IgG from passive transfer, IgG production begins at 4 
weeks, while hypogammaglobulinemic calves with low passive transfer begin producing 
antibodies at 7 days of age (Logan et al., 1974). 
1.1.1 Maternal Immunoglobulin 
Maternal immunoglobulin, transferred from dam to offspring, can have lifesaving, disease-
sparing effects for a variety of neonatal infections. The proportions of immunoglobulin classes 
(IgG, IgM, and IgA) in the colostrum and milk are variable among species. In cattle, the neonate 
receives passive immunity via maternal antibodies in both the colostrum and milk. IgM and IgA 
occur at relatively low concentration in ruminant colostrum and milk. IgG is the primary Ig in 
serum, and in cattle is also the primary Ig in both colostrum and milk. These antibodies are 
responsible for identifying foreign pathogens, which are then recognized by macrophages and 
neutrophils enabling their eventual destruction by phagocytosis or through the activation of the 
complement cascade.  
In cattle there are several subclasses of IgG. IgG1 and IgG2 are the major 
immunoglobulins, occurring in similar proportions in serum. In contrast, IgG1 comprises the 
primary immunoglobulin in bovine colostrum and milk (Barrington, Besser, Davis, et al., 1997). 
IgG1 and 2 differ structurally in the hinge sites and CH2 domains involved in binding to Fc 
receptors. IgG1 is the major antibody of secondary immune responses, primarily recognizing 
bacterial toxins and viral proteins, while IgG2 primarily recognizes the polysaccharide coatings of 
bacteria such as Streptococcus pneumonidae and Haemophilus influenzae (Vidarsson et al., 2014). 
Only IgG1 can be transferred, through specific receptors, from the circulation to the nasal and 
intestinal mucosa for additional protection at major sites of pathogenic challenge. 
1.1.2 Colostrum and Passive Protection of the Newborn 
Colostrum is the nutrient and immunoglobulin-rich first secretion of the mammary gland 
of mammals following parturition. Its purpose is to provide energy and immediate immunity to 
the neonate and thus it has a significantly different nutrient and immunological profile from milk. 
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Colostrum production and composition are influenced by breed genetics (Barrington et al., 2001; 
Norman et al., 1981). It is assembled during the five-week dry/non-milking period leading up to 
calving when the upregulation of lactogenic hormones signals the accumulation of lacteal 
secretions and serum components in the udder. This accumulation ceases at parturition most likely 
due to increases in prolactin concentration at the onset of lactation (Barrington et al., 2001; 
reviewed in, Foley & Otterby, 1978; Larson et al., 1980; Rincheval-Arnold et al., 2002). Colostrum 
is harvested as the udder is suckled or milked in the first 1 to 3 days postpartum. The components, 
including the immunoglobulin, are rapidly depleted by milking or suckling and/or are diluted in 
concentration by the influx of milk, produced starting at parturition.  
While colostrum and milk are both udder secretions that provide nourishment to support 
the growing calf, the composition of each varies substantially. Both contain protein, fat, and 
micronutrients, however, colostrum has double the solids, twice as much fat, and four times the 
total protein compared to milk (reviewed in, Foley & Otterby, 1978; Playford & Weiser, 2021). 
Additionally, colostrum is richer in oligosaccharides, growth factors, antimicrobial compounds, 
and immune components than the milk (Davis & Drackley, 1998; Gopal & Gill, 2000; Quigley & 
Drewry, 1998). Fat, present in higher concentration in colostrum, provides energy for 
thermogenesis in the initial days following birth (Davis & Drackley, 1998). Energy and vital 
micronutrients work synergistically to initiate metabolism and stimulate the development of the 
digestive system in the neonate (Davis & Drackley, 1998). As well as immunoglobulins, colostrum 
provides other important immune factors and non-specific anti-microbial factors such as insulin-
like growth factor (IGF1), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-a), and 
lactoferrin which provide non-specific protection (Reiter et al., 1975; Wheeler et al., 2007). 
Lactoferrin in colostrum is bacteriostatic, binding iron and transporting it to intra-cellular sites, 
preventing uptake by bacteria and viruses in the gut. IGF-1, important for neonatal growth, is 
present at 4 to 62 times greater quantity in colostrum versus milk (Odle et. al., 1996). Additionally, 
colostrum is rich in casein, α-lactoglobulin, and ß-lactalbumin providing amino acids for protein 
synthesis and lean muscle development (reviewed in, Tizard, 2018).  
Arguably, however, immunoglobulin is the most important component of maternal 
colostrum and the source of the majority of passive protection of the newborn. For the 
immunologically naïve bovine neonate, birth into an unsterile environment ensures immediate 
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challenge by environmental pathogens at the intestinal and respiratory mucosa. To ensure that 
maternal colostrum contains high levels of antibodies to these enteric and respiratory pathogens, 
many herds vaccinate the heifers and cows in the weeks prior to parturition with vaccines to benefit 
the calf. During this period, pregnant animals receive systemic vaccines to pathogens such as 
BRSV, PI3, rotavirus, coronavirus, and E. coli, the main respiratory and enteric pathogens of the 
neonatal calf. The immunoglobulin profile of colostrum synthesized during this period represents 
the systemic immunity of the dam and as such should provide broad-spectrum protection, 
representative of the antigen exposure obtained through vaccination of the mother as well as 
through natural exposure.  
A number of physiological features help to ensure the immunoglobulins and other factors 
in the colostrum are protected from degradation in the digestive tract of the calf. These include 
reduced protease activity in the gut of the newborn calf and presence of trypsin inhibitors in the 
colostrum, both of which prevent digestion of proteins such as immunoglobulin (reviewed in 
Godden et al., 2019). Additionally, suckling stimulates the formation of the esophageal groove, a 
series of muscular folds from the reticulorumen that allow colostrum or milk to bypass the rumen, 
reticulum, and omasum, delivering milk directly to the abomasum of the neonate. Thus, colostral 
proteins quickly reach the small intestine intact where they are taken up by intestinal epithelial 
cells through pinocytosis. Immunoglobulins are transported across the lamina propria via the FcRn 
receptor which binds to IgG1, and released into the lymphatic circulation by exocytosis, ensuring 
the newborn receives a large infusion of maternal immunoglobulins (Barrington, Besser, Davis, et 
al., 1997; Staley et al., 1972).  
Passive transfer of maternal immunity occurs during the first 24 hours after birth when the 
gastrointestinal (GI) tract of the neonate is “open” and is able to non-selectively absorb large 
molecular weight proteins. Intestinal permeability begins to decline rapidly after birth as the FcRn-
bearing enterocytes are replaced by cells that do not express this receptor (reviewed in, Tizard, 
2018). The process through which the intestinal cells gradually cease absorbing macromolecules 
is called “closure”. This process begins immediately after birth. The efficiency of Ig absorption 
across the intestinal epithelium decreases linearly until complete closure at 12-24 hours post-
partum (Staley & Bush, 1985). 
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Good quality maternal colostrum (MC), capable of successful passive transfer contains 50 
to >100g/L of immunoglobulin, equivalent to a Brix refractometer score of at least 23%. The IgG 
class comprises 85 to 90% of those antibodies, most of which is IgG1 (Barrington, Besser, Davis, 
et al., 1997; reviewed in, Foley & Otterby, 1978). Where IgG1 and 2 are equally represented in 
the serum, selective transport across the mucosal surface and into the udder results in 7x higher 
concentrations of IgG1 in the colostrum than in the serum (Larson et al., 1980). Re-secretion of 
the IgG1 from colostrum onto mucosal surfaces in the first weeks of life protects newborn calves 
from respiratory and enteric diseases. About 68% of the colostral IgG1 absorbed was shown to be 
re-secreted into the gut (Besser et al. 1988) and recent studies have demonstrated the appearance 
of IgG1 BRSV specific antibodies in nasal secretions collected from newborn calves fed colostrum 
containing BRSV specific antibodies (Ellis et al., 2018). Good quality maternal colostrum is an 
essential part of nutrition and disease management programs in cattle operations, providing broad-
ranging nutritional benefits and immunological protection at multiple sites.  
1.1.3 Milk and Passive Protection of the Suckling Neonate 
At parturition, increasing prolactin levels and other endocrine changes signal a transition 
of the mammary gland from the state of serum IgG1 accumulation that defines colostrum 
production, to one of milk production (Barrington et al., 2001; Rincheval-Arnold et al., 2002). The 
hormonal changes that occur at parturition also signal plasma cells from the GI tract to migrate to 
the mammary gland via the blood, where their uptake is regulated by locally produced chemokines 
(Wilson & Butcher, 2004). The colostrum is consumed by the calf and/or removed by milking 
and/or the components present diluted by milk secretion. The proportions of the components of 
colostrum and milk are similar, but the scale changes markedly. However, while the sharp decrease 
in concentration of colostral components present in the milk may imply a simple dilution effect, 
milk is also a complex and unique biologic, nutritionally complete and potentially providing calves 
with a broad range of critical protections to pathogens local to the udder and, potentially, to the 
gastrointestinal tract (GI tract). However, due to physical and physiological changes in the calf, 
that protection differs from that offered by the colostrum. 
While the predominant Ig in both colostrum and milk is IgG1, the concentration and 
proportion of Igs relative to other proteins changes dramatically in the transition from colostrum 
to milk production. At first milking, bovine colostrum contains approximately 14-16% (w/w) total 
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proteins compared to only 3% (w/w) in milk (reviewed in, Godden et al., 2019). Immunoglobulins 
comprise 80-90% of the total protein content of colostrum at 42-90 g/L, while in milk, that value 
drops to between 0.2 and 0.9g/L (reviewed in, Godden et al., 2019; Guidry, Paape, et al., 1980). 
In the transition of lacteal secretions, the most notable change is the increased representation of 
IgA in the milk, which increases from approximately 5% of colostral Igs to an average of 15% 
during lactation (Guidry, Paape, et al., 1980). Interestingly, only 30% of IgG and 10% of IgA in 
the milk is serum derived. The rest is derived locally from plasma cells in the udder (reviewed in, 
Hurley, 2003).  
Due to the process of gut closure to non-selective absorption occurring so quickly and 
completely in the neonate, the antibodies in milk are not absorbed systemically. Instead, once they 
enter the gastrointestinal tract, some proportion provide direct protective benefits, agglutinating 
free antigen, preventing attachment until the invader can be digested or excreted (Arthington et al., 
2002; Berge et al., 2009; Besser, McGuire, et al., 1988; Castrucci et al., 1984; Parreño et al., 2010; 
Saif et al., 1983). In numerous studies in piglets passive protection in the gut has been shown to 
be mediated by free IgA or IgG in the milk when high levels are maintained throughout lactation 
(Saif & Smith, 1985). That protection can be mediated by either Ig class and is facilitated by other 
co-factors found in the milk such as lactoferrin, lysozyme, fatty acids, and complement (Saif & 
Smith, 1985). 
Milk potentially provides a different range of immunoglobulin protection to that of 
colostrum, due to the translocation of plasma cells from the gut into the udder at lactation, and 
immune responses following the potential exposure to non-systemic pathogens through the streak 
canal. Thus, antibodies in the milk may be directed primarily to pathogens found locally in the 
udder, and/or other agents targeting other mucosal surfaces. Mastitis, or the inflammation of the 
mammary gland, is caused primarily by pathogenic bacteria that move into the udder through the 
streak canal during the lactation period. Infiltration of mastitis-causing bacteria such as 
Streptococcus, Staphylococcus and coliforms result in acute upregulation of the innate immune 
system and an increase in immune components in the milk (Oviedo-Boyso et al., 2007). Protection 
from these pathogens require the presence of secreted antibody (Tzipori, 1981; Snodgrass & Wells, 
1978). Variability in the immune components of milk can be attributed, in part, to the origin of Ig 
producing plasma cells and also the local antigen challenges faced by the mammary gland.  
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1.1.4 Antibody Classes, Subclasses and Specificities in Colostrum vs. Milk 
While the nutritional differences between colostrum and milk are well established, 
questions around the disease sparing impact of the two lacteal secretions remain. In the face of 
pathogenic challenge, the specificity, amount, viability and types of antibody present at the 
challenge interface is key. This makes both secretions potentially interesting targets for further 
research as to how they are best utilized for improving calf health and performance.  
IgG is the primary immunoglobulin in the serum of all mammals and it has a major role in 
antibody-mediated defenses. Antibodies are responsible for identifying foreign pathogens, which 
are then recognized by macrophages and neutrophils, enabling their eventual killing by 
phagocytosis or through the activation of complement. In cattle, this class can be further 
subdivided into the subclasses IgG1, IgG2, IgG3, and IgG4. Each subclass is comprised of slightly 
different amino acid sequences, affecting their electrophoretic mobility and contributing to 
different biological activities. For example, IgG2 agglutinates antigen particles and binds to a 
unique Fc receptor on macrophages and neutrophils, while IgG1 does not (reviewed in, Tizard, 
2018). Normal adult bovine sera contains roughly an equal amount of IgG1 and 2, however, both 
bovine colostrum and milk are comprised primarily of IgG1 (reviewed in, Butler et al., 2015).  
In mammalian species where IgG is transferred to the fetus prior to birth (ie., human, mice), 
IgA is the primary lacteal Ig component. In species where there is no transfer prior to parturition 
(ie. ruminants), IgG is the primary lacteal Ig. At parturition bovine colostrum is composed of 
approximately 24-80g/L IgG (90% of which is IgG1), 3-13g/L IgM, and 1-7g/L IgA (reviewed in, 
Tizard, 2018). Colostral immunoglobulins are concentrated in the mammary gland in late gestation 
by transportation across the mammary epithelium into the cistern of the udder (reviewed in, 
Hurley, 2003), at a rate of up to 500g IgG per week (Brandon et al., 1971). This translocation 
occurs via receptor-mediated processes; the neonatal Fc receptor (FcRn) for IgG1 and 2 (Guidry, 
Butler, et al., 1980), and the pIGR receptor for IgA and IgM (Mostov & Kaetzel, 1999). In 
colostrum, 100% of IgG and IgM and 50% of IgA are derived from the serum of the dam (reviewed 
in, Butler et al., 2015). Thus, the bovine neonate receives passive immunity through the colostrum 
that is mainly representative of the serum-borne antibody repertoire of the mother, heavily 
weighted to the IgG1 subclass.  
In cattle, the primary Ig of milk remains IgG1. Unlike humans, IgA never becomes the 
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principle Ig although the proportion of IgA in the milk does increase substantially from that of the 
colostrum (reviewed in, Butler et al., 2015; Larson et al., 1980; reviewed in, Tizard, 2018). In 
contrast to antibody-rich colostrum, bovine milk is composed of only 0.5-7.5g/L IgG, 0.1-0.2g/L 
IgM, and 0.1-0.5g/L IgA. Although the total concentration of Ig is low in the milk, it is important 
to consider that the large volume of milk produced results in overall larger mass of Ig in milk 
relative to that in colostrum which is produced at much lower volume and for very short duration 
(Butler, 1981; Mach & Pahud, 1971). 
There is currently debate regarding the origin of plasma cells in the mammary gland of 
cattle at lactation. Near parturition and during early and late lactation, hormonal changes signal 
the migration of gut-associated lymphoid cells (GALT) from the intestinal mucosa into the 
mammary gland (Gibson et al., 1991; Roux et al., 1977). The GALT is the largest organ of the 
immune system. It is comprised of Peyer’s patches, lymphoid and myeloid cells in the lamina 
propria, as well as intraepithelial lymphocytes (Ishikawa et al., 2005; Spenser et al., 2007). The 
mechanism of trafficking GALT cells to the mammary gland is currently poorly understood but is 
believed to be provoked through changing serum concentrations of estrogen, prolactin, and 
progesterone (Barrington, Besser, Gay, et al., 1997; Barrington et al., 2001; Lascelles & 
McDowell, 1974; Rincheval-Arnold et al., 2002; Smith et al., 1971). The precursors of IgA-
producing plasma cells have been identified as originating in the GALT and moving into the 
mammary gland during early and late parturition (Tanneau et al., 1999). However, these 
lymphocytes are phenotypically more similar to peripheral, rather than intestinal lymphocytes, 
leading some to question their origin (Bosworth et al., 1993).  
The FcRn expression that facilitates IgG1 transfer coincides with the onset of 
colostrogenesis but decreases rapidly at the onset of lactogenesis. As FcRn receptor function 
declines and non-specific intestinal permeability abates, the steady, substantially decreased, 
presence of antibodies in the udder throughout lactation is believed to be mainly derived from the 
secretions of local plasma cells (Barrington, Besser, Gay, et al., 1997). Additionally, serum 
transport of IgA into the mammary gland in cows either does not occur or occurs at a very slow 
rate suggesting that IgA in cow milk is synthesized locally in the udder (Butler et. al., 1972, 1986). 
Additionally, organ culture studies have shown synthesis of both IgG1 and IgA in the mammary 
gland (Butler et. al., 1972; Sordillo & Nickerson, 1988). Local synthesis of Igs in the mammary 
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gland is also supported by immunohistochemical staining showing the location of IgA and IgG1 
plasma cells in the mammary glands of ewes, sows and cows (Chabaudie et al., 1993; Collins et 
al., 1986; Fragkou et al., 2007; Mayer et al., 2002, 2005; Salmon, 1987, 1999; Salmon & Delouis, 
1982). In sows, studies of radiolabelled Igs show 70% of IgG and more than 90% of IgA and IgM 
found in milk are synthesized locally in the mammary gland (Bourne & Curtis, 1973). In cows, 
some local synthesis of IgG1 has been demonstrated during lactation (Sheldrake & Husband, 
1985). Additionally, the bovine udder has been shown to respond to stimulation through local 
immunization with the secretion of antibodies (Lascelles & McDowell, 1974; Smith et al., 1999). 
Although IgA and IgM are the primary antibodies produced. Systemic priming, followed by 
mammary gland immunization has also been demonstrated to lead to increased and sustained local 
antibody production capable of lasting through lactation (Watson & Lascelles, 1975). Ultimately 
it is believed that in milk, only 30% of IgG and 10% of IgA are serum-derived, the rest are thought 
to be locally-derived from resident plasma cells (reviewed in, Butler et al., 2015; reviewed in, 
Hurley, 2003). 
The movement of lymphocytes between the GALT system and the mammary gland could 
provide a direct link between the broader maternal mucosal system and the secretory immune 
repertoire of the udder, potentially providing protective antibodies for any pathogens inhabiting 
the intestine or other mucosal tissues (Brandtzaeg, 2003, 2010; Hanson & Korotkova, 2002). This 
process may explain the differences in concentration, proportion and perhaps specificity of 
immunoglobulin between colostrum and milk as lactogenesis begins and the colostrum is replaced 
completely with milk.  
Milk contains many of the components necessary to provide passive transfer of immunity 
to neonates if used as a colostrum replacement. However, due to the source of the antibody 
(primarily localized antibody production), milk may provide a different range of protection 
directed primarily to pathogens found locally in the udder and/or other mucosal surfaces (for 
example, Streptococcus, Staphylococcus and coliforms that enter through the streak canal, as well 
as to rotavirus and other mucosally-targeted pathogens) rather than the broad systemic protection 
afforded by colostral antibodies. 
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1.2. Failure of Passive Transfer of Immunity 
Failure of passive transfer of immunity (FPTI) occurs when the concentration of IgG in the 
serum of the calf, considered consistent with neonatal health, is not reached prior to gut closure. 
This results in a physiological state which leaves the neonate susceptible to infection and disease 
(Heinrichs et al., 1994; USDA APHIS | NAHMS Dairy Studies, 2010, 2018). Passively acquired 
circulating antibodies provide protection against systemic infections, and through re-secretion onto 
mucosal surfaces, against enteric infections (Besser, Gay, et. al., 1988; Besser, McGuire, et. al., 
1988; Saif & Smith, 1985, Ellis et al 2018). FPTI outcomes can be devastating to both individual 
producers and industry. FPTI can result in economic insufficiencies in commercial production, 
such as reduced first and second lactation milk production in heifers and even death losses (USDA 
APHIS | NAHMS Dairy Studies, 1996, 2018; Wells et al., 1996). 
In the United States, pre-weaned dairy calves have an average mortality rate of between 5-
11% (Urie et al., 2018; USDA APHIS | NAHMS Dairy Studies, 1996, 2018). Of these, up to 35% 
of calf mortalities are attributed to failure of passive transfer (FPTI) of maternal antibodies from 
colostrum (Brignole & Stott, 1980; Stott et al., 1979a; Urie et al., 2018; Wells et al., 1996). In a 
study by McGuire et. al., 85% of calves less than three weeks old that died of infectious disease 
had failure of passive transfer of immunity (McGuire et al., 1976). There is a well-established 
relationship between BRD in calfhood and decreased milk production, reproduction and early 
culling (Stanton et al., 2012). 
In dairy calves, passive transfer of maternal antibodies was traditionally considered 
successful and consistent with protection from mortality when neonatal serum IgG levels are 
greater than 10 mg/ml at 24 to 48 hr following birth ((Beam et al., 2009; Besser & Gay, 1994; 
Weaver et al., 2018). However recently the targets for passive transfer have been revised to the 
considerably higher levels considered necessary to protect from disease morbidity. New research 
recommends neonatal serum IgG level minimums of 15g/L, and higher serum IgG should be 
targeted for enhanced protection (Lombard et al., 2020; Urie et al., 2018). For beef calves the 
currently recommended target is even higher at 24-25g/L IgG (Dewell et al., 2006; Waldner & 
Rosengren, 2009). Achieving effective passive transfer of maternal immunity in neonates can be 
complicated as several factors impact the absorption of maternal Ig by the neonate. The mass of 
Ig consumed is critical; the mass is a function of the Ig concentration in the colostrum and the 
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volume consumed. The Ig concentration of IgG in maternal colostrum can vary greatly among and 
within farms, ranging anywhere from 7 to >150 g/L (Swan et al., 2007; USDA APHIS | NAHMS 
Dairy Studies, 2010). Good quality maternal colostrum, capable of providing adequate passive 
transfer, should be >50 g/L IgG (Godden, Haines, Konkol, et. al., 2009). In some studies up to 23-
35% of colostrum does not meet that requirement (Quigley et al., 2013; Shivley et al., 2018; USDA 
APHIS | NAHMS Dairy Studies, 2010, 2018). In addition to low Ig concentration, low colostrum 
volume is not uncommon, especially among first calf heifers (Gavin et al., 2018). Providing calves 
with 3-4L of high-quality colostrum (at least 150g/L total IgG) within 1-2 hours after birth is the 
gold-standard for colostrum management programs. To this end, farms have traditionally stored 
and/or pooled excess maternal colostrum to supplement calves when maternal colostrum is deemed 
inadequate in quality or quantity to attempt to ensure all calves receive an adequate supply. 
However, this is a cumbersome process, prone to shortages and risks of pathogen contamination 
and inevitably results in highly variable colostrum management. Farms that pool colostrum from 
a variety of lactating dams are 2.2 times more likely to have calves with FPTI than those that do 
not pool colostrum (Beam et al., 2009). Another strategy to prevent FPTI is to supplement or 
replace maternal colostrum with commercial colostrum products (Haines et al., 1990), which 
potentially provides convenient, broad-spectrum immunity to calves.  
1.3. Colostrum Replacement Products 
The implementation of passive immunization strategies to prevent and treat infectious 
diseases in production animals is largely dependent on cost and effectiveness compared with 
existing solutions such as vaccination and treatment with antibiotics. Ideally, products must be 
easy to obtain and use, be broadly applicable, and integrate with existing vaccine and diagnostic 
management strategies. For antibody products, sourcing high volume, low cost, pertinent pathogen 
specific antibodies is of primary importance in the development of commercial products for 
managing passive immunization strategies in production facilities.  
In 1950, Parrish et. al. (1950) first reported the composition of bovine colostrum (Parrish 
et al., 1950). Maternal colostrum was increasingly recognized as a critical source of nutrition for 
the neonate in addition to providing passive immunity by the absorption of Ig. As understanding 
of the biology of neonatal calf diets improved, it became apparent that protein concentration and, 
in particular, immunoglobulin concentration in the first colostrum feeding is more important than 
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the volume of colostrum fed and there was much important work conducted defining parameters 
of colostrum feeding, timing, and quality (Bush & Staley, 1980; reviewed in, Butler et al., 2015; 
Stott et al., 1979b, 1979c, 1979d). These studies laid the foundation for the many more recent 
studies that have culminated in the current recommendations (Beam et al., 2009; reviewed in, 
Godden & James, 2020; Lombard et al., 2020; Urie et al., 2018). 
The development and availability of colostrum replacer (CR) products offers a 
standardized and convenient means of providing high quality and consistent passive protection 
and nutrition to calves while reducing the risk of pathogen exposure associated with unpasteurized 
lacteal fluids and thereby potentially breaking the transmission cycles of some infectious diseases. 
Supplementation with reputable commercial products provides the benefit of administering a 
known mass of IgG. The bovine immunoglobulin in these products can be obtained from a variety 
of sources including pooled colostrum, bovine serum, and/or milk whey, and could offer a broad 
range of protective antibodies to common bovine pathogens (Davis & Drackley, 1998; reviewed 
in, Godden & James, 2020; McGuirk & Collins, 2004).  
Commercial colostrum products fall into two main categories, colostrum supplements (CS) 
and colostrum replacers (CR) (reviewed in, Godden & James, 2020). Supplements are designed to 
supplement maternal colostrum. These products do not have to show prevention of FPTI. As such, 
each portion of CS product provides between 50 to 100g in 1-2 L volumes (reviewed in, Godden 
& James, 2020). CR products must contain sufficient IgG mass to ensure adequate passive transfer 
without access to maternal colostrum, typically 150-200 g IgG. 
Studies have shown that when administered within the first hours after birth and in high 
enough Ig mass (150 to 200 g IgG), commercially prepared CR products, similarly to pooled 
maternal colostrum, can result in acceptable passive transfer levels and absorptive efficiencies 
(Arthington et al., 2000; reviewed in, Cabral et al., 2012; Foster et al., 2006; Godden, Haines, & 
Hagman, 2009; Godden, Haines, Konkol, et al., 2009; Pithua et al., 2009; Place et al., 2010; 
Priestley et al., 2013; Quigley & Bernard, 1996; Santoro et al., 2004; Shea et al., 2009). High 
quality colostrum collected and pooled from North American dairy farms have antibodies to all 
common, endemic pathogens such as E.coli, rotavirus, and BRSV through natural exposure and/or 
through vaccination programs. In some cases, commercial products may prove superior to 
maternal colostrum (MC). In one study, calves fed a CR product had a reduced risk of testing 
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positive to infection with Mycobacterium avium subsp. paratuberculosis (7.6% test positive, odds 
ratio 0.52 [0.27 to 1.003]), compared to maternal colostrum-fed control calves (11.9% test 
positive), suggesting that MC may be a vector for Mycobacterium avium subsp. paratuberculosis 
(Pithua et al., 2010).  
Colostrum replacer (CR) products should enable the feeding of a known IgG mass to ensure 
the magnitude of passive transfer of immunity in calves. However, the results of colostrum replacer 
trials have been mixed with many early to market products failing to provide the minimal 10g/L 
calf serum IgG (Quigley et al., 2001; Swan et al., 2007). In a trial of 12 dairy herds, 239 calves 
were fed a serum -derived CR product containing 125g of IgG vs 218 calves fed maternal 
colostrum. Both groups were then supplemented at 8 to 12 hours with 1.9 L of MC, for the MC-
fed group, and 1.9L of milk replacer supplemented with 45g plasma-derived CS for the CR-fed 
group. CR-fed calves had significantly lower serum IgG concentrations at 5.8g/L compared to MC 
fed calves at 14.8g/L. In this study, preweaning morbidity and mortality rates were the same and 
high for both groups; 59.6% morbidity and 12.4% mortality for CR fed and 51.9% morbidity and 
10% mortality for MC fed calves (Swan et al., 2007). In contrast, Pithua et. al. found that calves 
fed a colostrum-derived CR containing 200g IgG were significantly less likely to have failure of 
passive transfer of immunity than calves fed 3.8L of 21g/L pooled maternal colostrum. In this trial, 
only 11% of calves fed CR experienced FPTI, while 70% of MC fed calves had FPTI (Pithua et 
al., 2013). The magnitude of this discrepancy however is due to the atypically low IgG of the 
pooled maternal colostrum fed to the control group. Further, in a national survey where the average 
maternal colostrum contained 64.3g/L maternal colostrum, calves fed still experienced 23% FPTI 
(Smith, 2014), which was significantly greater than the neonates fed colostrum derived CR product 
in the above referenced study.  
In general, studies of commercial products reporting the most success in achieving > 10g/L 
passive transfer have fed >100g IgG in the first hours following parturition (Mee et al., 1996; 
Quigley et al., 2001). In one such study, calves were fed 100g or 200g IgG from CR products, vs 
3.78L MC, calf serum IgG levels at 24 hours were reported as 11.6, 16.9, and 27.2 g/L total IgG, 
respectively (Foster et al., 2006). More recent studies emphasize the benefits of feeding larger IgG 
mass to achieve higher serum IgG concentrations (reviewed in, Godden & James, 2020; Hare et 
al., 2020; Lombard et al., 2020; Urie et al., 2018). In fact, data from the USDA’s N.A.H.M.S. 
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Dairy study (2018), report greater probability for survival in calves with passive transfer levels 
>15g/L IgG (reported in: Urie et al., 2018). Other studies report decreased susceptibility to 
respiratory infections at >15g/L total IgG (Furman-Fratczak et al., 2011), and reduced mortality 
rates in calves at passive transfer levels as high as 20g/L total IgG (Chigerwe et al., 2015). 
While it is well accepted that passive transfer outcomes are highly dependent upon IgG 
mass fed, another potential explanation for differential success in CR replacement studies is the 
source of bovine immunoglobulin. Colostrum replacer ingredients are divided into 4 categories: 
dried colostrum products, milk/whey protein products, plasma or serum-based products, and 
products that are a combination of some or all of the previous categories. Bovine serum is Ig-rich, 
affordable and readily available from slaughterhouses. Adult bovine serum is composed of an 
equal ratio of IgG1 and IgG2, in comparison to the IgG1-rich colostrum. Immunoglobulin 
comprises approximately 20% of spray-dried, blood plasma dry matter (Pierce et al., 2005; 
Quigley & Drew, 2000), that can be further purified and concentrated (Lihme et al., 2010). 
However, there is evidence that products formulated from serum have lower apparent percent 
efficiency of absorption (AEA) of immunoglobulin than those made from natural colostrum 
(Arthington et al., 2000; Brakefield et al., 2010; reviewed in, Cabral et al., 2012; Godden et al., 
2016; reviewed in, Godden & James, 2020; Godden, Haines, & Hagman, 2009b; Godden, Haines, 
Konkol, et al., 2009; Morrill et al., 2010; Pithua et al., 2013; Santoro et al., 2004; Shea et al., 2009). 
Apparent efficiency of absorption of immunoglobulins (AEA%) is a metric of evaluating passive 
transfer efficiency, determined using the amount of IgG fed, calf serum IgG level, and calf body 
weight (Quigley et al., 2002). In the fifth and sixth editions of the textbook Large Animal Internal 
Medicine (2014, 2020), Godden published a review of study results from products tested up to 
2018 and these data support the suggestion that products produced from colostrum have superior 
absorptive characteristics relative to those that utilize immunoglobulin from other sources 
(reviewed in, Godden & James, 2020; Smith, 2014). It is therefore conceivable that the source of 
Igs and the increased proportion of IgG1 found in colostrum-derived replacer products provide 
immunological advantages over serum-derived products, potentially resulting in improved calf 




Given the purported superior efficacy of colostrum-based CR products, the collection of 
excess dairy colostrum is a logical source of bovine-specific antibodies. However excess dairy 
colostrum is limited in supply, expensive to collect and process. Consequently, other sources of 
bovine immunoglobulin have been sought to create colostrum “formulas”. These include the use 
of milk whey, a by-product of cheese manufacture (Haines et al., 1990). The ratios of Igs and Ig 
subclasses in milk are similar to those of colostrum and while the levels of IgG are low in milk 
compared to colostrum (0.5-1.0g/L vs 20-200g/L, respectively) there are methods to concentrate 
the IgG thereby providing a relatively inexpensive source of immunoglobulin (Hurley & Theil, 
2011; Siso, 1996; USDA APHIS | NAHMS Dairy Studies, 2010, 2018). Thus, some commercial 
products for colostrum replacement may contain immunoglobulin derived from milk rather than 
colostrum. Currently there are no studies that have examined the specificities of antibodies in milk 
whey derived products to investigate whether these differ from those in colostrum and/or that this 
practice may result in products with different efficacy in newborn calves. One study of the whey-
based product Colostrx (Colostrx CR Colostrum Replacer; Agrilabs, St. Joseph, MO) claims to 
provide a comparable level of clinical protection to colostrum in an E. coli F5 (K99) challenge 
model (Harman et al., 1991). E. coli is the most common cause of septicemia and diarrhea in 
calves, causing substantial financial losses for individual farmers as well as commercial beef and 
dairy industries (Kolenda et al., 2015). Given the belief that milk antibody production is localized 
in the udder by GALT cells that migrate from the intestine, coincident with the onset of lactation, 
milk antibodies could potentially be used to provide protection to common and economically 
important pathogens such as E. coli, in the form of increased antibody levels to enteric and 
localized udder pathogens. 
Among the concerns arising with the use of CR products has been the capacity of colostrum 
and colostrum replacement products to transmit disease. Standard milk pasteurization conditions 
may result in viscous, coagulated colostrum due to its higher protein concentration. However, 
calves fed colostrum heat-treated for 1 hr at 60°C have shown successful outcomes in the form of 
successful passive transfer and/or decreased morbidity, particularly due to diarrheal agents. In one 
study of 1093 calves, half were fed fresh colostrum and half were fed heat-treated colostrum. The 
calves fed heat-treated colostrum had high passive transfer levels and better AEA than those fed 
fresh colostrum (18mg/ml total IgG compared to 15.0mg/ml, respectively). Additionally, in this 
study calves fed pasteurized colostrum were less likely to require treatment events, particularly 
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due to scours, than those fed fresh colostrum (30.9% vs 36.5%, respectively) (Godden et. al., 
2012).  
Colostrum products are almost always manufactured to a dry powder that is reconstituted 
with water prior to feeding. Chelack et. al. (1993), compared three methods of drying colostrum, 
concluding that spray-drying was the most cost-effective method. Calves fed a total of 126g IgG 
in two 1L feedings of either maternal colostrum or spray-dried colostrum had equivalent serum 
IgG concentrations at 48h (10.57g/L and 11.6g/L, respectively). There are few subsequent 
published studies that have addressed the best methods for producing commercial products as the 
information is regarded by manufacturers as proprietary. Regulatory agencies currently allow 
licensed colostrum products to be either heat treated or irradiated as long as the safety of the 
methodology is demonstrated to the agencies. However, these results are proprietary.  
Colostrum products that are licensed by the USDA and CFIA with claims to prevent FPTI 
are considered in the class of therapeutics termed “veterinary biologics” which also comprises 
vaccines and antibody products such as anti-sera. Only CR products derived from colostrum are 
eligible for inclusion and allowed to have these claims. All others are marketed as “feed” products 
although many manufacturers typically market these products as de facto colostrum replacers with 
claims to prevent FPTI. Licensed CR products must be produced in federally inspected plants and 
must undergo regular purity and potency testing to ensure they do not exceed specified bacterial 
counts and are free of coliforms, Salmonella spp., and fungi. They are also tested for efficacy so 
that within 24hrs post-treatment, 90% of animals that receive this product must have total serum 
IgG measurements at least equal to the USDA-APHIS approved IgG Species Standard (Canadian 
Food Inspection Agency, n.d.; USDA 2007, 2014). Colostrum for these products is collected from 
certified dairies, frozen, then later thawed, pooled, heat treated or treated with ionizing radiation, 
spray dried and packaged. Aside from the loss of cellular components such as bacteria and 
leukocytes, these products will be very similar in composition to fresh maternal colostrum. 
Colostrum replacement products derived from milk whey or blood cannot be licensed by 
federal regulatory agencies (CFIA and/or USDA) for use in newborn calves to prevent FPTI and 
are not legal in Canada however they may be sold as animal feed without a claim for providing 
immunoglobulin or passive immunity in the USA. In the US there are few FPTI licensed products; 
the vast majority of products promoted as “colostrum replacers” are actually animal feed products 
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and do not fall under USDA regulations for antibody products. While it is illegal to make passive 
transfer claims for such feed products this is not enforced. Licensed products are strictly regulated 
and may only contain colostrum as an antibody source, while “feed” products may contain 
antibodies sourced from colostrum, milk and/or blood.  
 Milk sourced antibodies, in contrast to blood, have many of the characteristics of colostral 
immunoglobulin. The first colostrum product widely marketed commercially (Colostrx) contained 
the immunoglobulin found in the milk whey fraction of cheese manufacture (Haines et al., 1990). 
This trade-name product is a feed rather than a FPTI licensed product and as such has undergone 
several subsequent iterations in ingredient source and the source of the immunoglobulin in this 
and other feed products is difficult to determine, and subject to change as manufacturers find 
alternative sources of ingredients. It is currently unknown how many of the many unlicensed CR 
products sold in the USA have milk whey as an immunoglobulin source.  
While it is relatively simple to measure the total mass of IgG administered in CR products 
and the resulting levels of passive transfer compared to feeding maternal colostrum there have 
been few studies focused on understanding the specificities of the antibody delivered to calves fed 
CR products. Chamorro et al (2014), reported that when calves were fed a colostrum based replacer 
(CR) with 208.5g IgG, vs those fed maternal colostrum with 277.4g IgG, the CR product provided 
calves with more uniform levels and predictable duration of persistence of antibody to common 
bovine respiratory viruses, while those fed MC had greater variation and overall shorter duration 
of detection of antibodies (Chamorro et al., 2014). Thus, feeding commercial products derived 
from high quality pooled colostrum may improve and provide a longer and more uniform level of 
protection. 
Colostrum replacer products are an increasingly accessible option on farms with limited 
labour and/or access to colostrum reserves, those with high numbers of heifers producing low 
volume and/or quality colostrum, or producers trying to break the cycle of transmission of many 
common bovine diseases. As the utilization of colostrum replacer products increases, research into 
the efficacy of these products has demonstrated that mass of IgG alone is not a sufficient predictor 
of either optimal passive transfer or calf performance. There have been no studies that have 
attempted to examine the differences in the source and/or the specificity antibodies from differing 
sources to understand if this may impact the utility of these products.  
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2. TRANSITION STATEMENT 
Early life immune status is an important variable contributing to health and future 
performance of calves. Colostrum is the vehicle through which important immune factors 
including immunoglobulin, growth factors and nutrients are transferred from the dam to the 
neonate. Following birth, the calf’s ability to absorb macromolecules is quickly reduced, and by 
24 hours the gut is almost completely closed to further uptake. Thus, the first feeding is the single 
most important meal a calf will consume in its lifetime. In a dairy calf, the initial feeding should 
provide at least 150-200g of Immunoglobulin G (IgG). When the dam does not provide sufficient 
quality or quantity of colostrum to the neonate, or for control of disease transmitted in colostrum, 
commercially available colostrum replacers (CR) products may be an appropriate alternative. 
Colostrum replacer products can be made from various sources, including colostrum, serum and/or 
milk whey. In colostrum, antibodies and co-factors are primarily serum-derived and the immunity 
should be representative of the history of systemic antigen exposure of the dam. In contrast, 
immunoglobulins in milk should be primarily derived from localized plasma cells, which migrate 
from the intestinal mucosa at parturition and during early and late lactation. Milk could therefore 
provide a different range of protection and may be primarily to pathogens found locally in the 
udder and mucosal surfaces (for example, Streptococcus and coliforms that enter through the 
streak canal). Calves fed milk sourced immunoglobulin, or CR products enhanced with milk whey 
IgG to increase total IgG content, may have lower specific antibody levels to systemic pathogens, 
compared to those fed colostrum. Because there is interest in the complete or partial 
supplementation of colostrum replacer products with whey derived from milk, it is important to 
characterize milk whey antibodies to determine if they are likely to be of equal or sufficient benefit 





The use of commercial colostrum replacer (CR) products enables producers to break the 
cycle of many common calfhood diseases transmitted in the colostrum, such as Johne’s disease. 
Use of commercial products also gives producers control over the quality and quantity of 
colostrum fed at parturition, facilitating the successful passive transfer of immunity in newborn 
calves. Identifying and understanding the specific antibodies of potential sources of bovine-
specific immunoglobulins could influence their use and potentially lead to better quality CR 
products and improved calf health and disease management outcomes. To further 
understanding in this area, the following objectives were addressed in this thesis: 
 
• The overall objective was to determine if there is differences in the magnitude of the 
specific antibodies in IgG found in serum, milk and colostrum in a group of normal dairy 
cows.  
• The specific objective was to estimate the magnitude of antibodies to a selection of 
pathogens including some considered to be found systemically and others considered to be 
more localized to the gut mucosa and udder 
• An additional objective was to determine if there are apparent differences among the 
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Abstract: 
In cattle (Bos taurus), the immunologically naïve newborn calf receives immune factors, growth 
factors and nutrients from the dam via the colostrum. Colostral antibodies are primarily serum-
derived and provide broad-spectrum protection representative of the systemic immunity of the 
mother. In contrast, immunoglobulins in milk are primarily derived from udder localized plasma 
cells, which migrate from the intestinal mucosa at parturition and during lactation. It is an 
increasingly common practise that newborn dairy calves are fed commercial colostrum 
replacement products containing IgG sourced from colostrum, milk and/or serum in addition to or 
instead of maternal colostrum. We hypothesized that IgG derived from milk will have lower levels 
of antibodies to systemic pathogens, compared to serum and colostrum. We sampled serum and 
colostrum (1-2hr post partum) and milk (day 5 post partum) from 24 dairy heifers or cows, 
measured total IgG using a radial immunodiffusion assay (RID) and determined specific antibodies 
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(IgG class) for a variety of systemic, gut and udder-associated pathogens (ie. bovine respiratory 
syncytial virus (BRSV), bovine herpes virus (BHV-1), parainfluenza 3 (PI3V), Streptococcus 
uberis, Staphylococcus aureus, E. coli F5 (K99), rotavirus and bovine coronavirus, via enzyme-
linked immunosorbant assay (ELISA). We also performed additional ELISAs to investigate the 
IgG1 and IgG2 subclass antibodies for BRSV, rotavirus and S. uberis. Wilcoxon signed rank tests 
(with Bonferroni correction, P<.017) indicate that colostrum derived IgG contains more antigen 
specific antibodies to BRSV (IgG H+L), PI3V (IgG H+L) S. aureus (IgG H+L), E. coli F5 (K99) 
(IgG H+L), and rotavirus (IgG H+L and IgG1) and BCV (IgG H+L), than the IgG from milk. In 
comparison to the serum, colostrum is higher in BRSV (IgG H+L and IgG1), BHV-1 (IgG H+L), 
PI3V (IgG H+L), E. coli F5 (K99) (IgG H+L), S. uberis (IgG H+L) and rotavirus (IgG1). Milk 
IgG contains more specific antibody to BRSV (IgG H+L and IgG1), BHV1 (IgG H+L), PI3V (IgG 
H+L), and rotavirus (IgG1) when compared to serum. Colostrum derived IgG delivers more 
specific antibodies to most endemic pathogens compared to the IgG found in milk or serum. 
However, milk IgG, similarly to colostrum has higher amounts of specific IgG1 and delivers a 
similar spectrum of antibodies. Thus, bovine milk IgG may be a superior source for the newborn 
calf compared to serum sourced IgG.  
 
4.1 Introduction:  
Ruminants, including cattle, are born almost agammaglobulinemic; neonates receive 
immunoglobulin from the dam in the “first milk”, or the colostrum (Gullickson et al., 1942). 
Colostrum is created during the five-week dry (non milking) period leading up to calving when 
the upregulation of lactogenic hormones signals the accumulation of lacteal secretions and serum 
components in the udder. It is depleted as the udder is suckled or milked in the first 1 to 3 days 
postpartum (reviewed in, Butler et al., 2015).  
Good quality maternal colostrum (MC), capable of successful passive transfer of immune 
protection to the neonate, contains 50 to >100g of immunoglobulin (reviewed in, Godden & James, 
2020; Shivley et al., 2018; Waldner & Rosengren, 2009). The class of antibodies found in 
colostrum is 85 to 90% IgG (reviewed in, Tizard, 2018). The major IgG subclass in colostrum is 
IgG1 that is primarily serum-derived. Thus the antibodies in colostrum represent the recent 
maternal immune response to both environmental pathogen exposure and vaccination history, 
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providing broad range protection to most ubiquitous calfhood pathogens (reviewed in, Butler et 
al., 2015 Barrington, Besser, Davis, et al., 1997; reviewed in, Foley & Otterby, 1978). Ensuring 
good quality colostrum is an essential component of nutrition and disease management programs 
in cattle operations.  
Colostrum replacement (CR) products have been commercially available for over three 
decades and can be used to supplement, or totally replace, maternal colostrum when maternal 
supplies are of limited quantity, poor quality, or are considered at risk of disease transmission 
(reviewed in, Godden et al., 2019). Studies of CR feeding trials have mixed results, but in general 
feeding 150-200g total IgG within the first few hours after birth results in successful passive 
transfer of immunity to neonates (reviewed in, Cabral et al., 2013; reviewed in, Godden & James, 
2020). While the obvious source of immunoglobulin for CR products is colostrum, even dairy 
cows produce colostrum in only modest quantities, making it expensive and difficult to obtain.  
A more readily available source of bovine IgG for CR products is plasma obtained during 
slaughter. Plasma derived IgG is, however, approximately equal amounts of IgG1 and IgG2 
subclasses. IgG2 cannot be re-secreted at mucosal surfaces; a critical protective advantage of IgG1 
which occurs at much greater abundance than IgG2 in colostrum (Besser, Mcguire, et al., 1988; 
Ellis et al., 2018). Thus, about half the IgG mass in blood sourced products may be of limited value 
in protection of mucosal surfaces of the neonate.  
Immunoglobulins in milk are far less abundant than in colostrum and are primarily derived 
from udder localized plasma cells, which migrate from the intestinal mucosa at parturition and 
during early and late lactation (only about 30% of IgG in milk is serum-derived) (reviewed in, 
Butler et al., 2015). Thus, milk likely contains IgG with specific antibodies primarily to pathogens 
found locally in the udder and at other mucosal surfaces.  
Milk derived IgG has been used as a source of immunoglobulin for CR products (Harman 
et al., 1991; Mee et al., 1996). However, the question of differences in the specificities of the 
antibodies compared to those found in the IgG of serum/plasma or colostrum has not been 
examined. The dairy industry harvests milk in large quantities and milk whey containing IgG is 
widely available as a by-product of cheese production. While the immunoglobulins in milk are at 
relatively low concentration, the volumes produced result in an overall large yield of antibodies 
that can be harvested and concentrated. In addition, in contrast to serum, the composition of IgG 
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subclasses in milk is identical to colostrum (primarily IgG1), allowing for re-secretion of milk-
derived antibodies at mucosal surfaces (reviewed in, Butler et al., 2015; reviewed in, Hurley & 
Theil, 2011). 
The goal of this study was to determine if there are differences in the amounts and 
specificities of antibodies in the IgG harvested from colostrum, serum and milk in a group of post 
parturient dairy cows to better understand if there can be benefits or disadvantages in using these 
IgG sources for passive immunity in newborn calves. 
 
4.2 Materials & Methods: 
Sample Collection:  
This study was approved by the University of Saskatchewan Animal Care committee (AUP 
#009CATA2018). Samples were collected from all cows and heifers calving within a two-week 
period at a commercial dairy farm in New York State. The 19 Holstein and 5 Brown Swiss dairy 
cows were maintained according to the routine management procedures of the farm. Serum and 
colostrum samples were taken at first milking, within 1-2hr of calving. Blood samples were 
collected from the tail vein into 10ml vacuum tubes. Blood was centrifuged at 1400krpm x 10 min 
and serum harvested into new 10ml tubes and frozen at -20C. Concurrently, a 10-25ml sample of 
first milking colostrum was collected and frozen at -20C. A milk sample was similarly collected 
from each cow on day 5 following parturition and also stored frozen. All samples were shipped 
frozen, then thawed and aliquoted on arrival at the testing laboratory. 
Measurement of IgG Concentration in Colostrum, Milk and Serum:  
IgG concentration was determined for each biologic using a single radial immunodiffusion 
assay (sRID) (Chamorro et al., 2017; Chelack et al., 1993b). Briefly, serum (diluted 1:4), milk 
(undiluted) and colostrum (diluted to a minimum 1:4) were diluted in 1x PBS and 4 uL samples 
deposited in wells punched in an agar matrix infused with antiserum to bovine IgG (Bethyl 
Laboratories Inc., Montgomery, Texas, USA). After 18 hours incubation at room temperature, a 
calibrating viewer (Transidyne General Corporation, Ann Arbor, Michigan, USA) was used to 
measure the diameter of the immunoprecipitin rings formed around the samples, which was 
compared to the regression curve of a serially diluted serum standard containing a known amount 
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of bovine IgG (Midland Bioproducts, Boone, Iowa, USA). Total serum proteins and Brix values 
were measured using a refractometer (Palm Abbe - Misco, Solon, Ohio, USA).  
Specific Antibody Values in the IgG of Colostrum, Milk and Serum:  
Enzyme-linked immmunosorbant assays (ELISAs) were performed as previously 
described (Durham & Sillars, 1986; Ellis et al., 2013) with modifications, to estimate the 
magnitude of specific IgG antibody (H+L) for BRSV, PI3V, BHV-1, rotavirus, bovine 
coronavirus, Escherichia coli F5 (K99), Streptococcus uberis and Staphylococcus aureus in the 
colostrum, milk and serum samples. Additional ELISAs for IgG1 and IgG2 subclasses were 
performed for BRSV, S. uberis and rotavirus. These targets were chosen to represent the 
respiratory, mastitis-associated and GI-associated pathogen groups. 
Prior to testing, utilizing the results of the sRID assays for IgG concentration, each sample 
was adjusted to 0.5 g/L IgG, such that all samples were tested in each assay at the same IgG 
concentration. For testing, samples were further diluted so that the expected range of values fell 
within the linear portion of a standard curve derived from serial dilutions of a positive control 
serum. Briefly, 96-well plates (Immulon IV; Thermofisher, Waltham, Massachusetts, USA), were 
coated with a carbonate coating buffer containing a heterogenous antigen preparation, purified 
from pathogen-infected cell lysates, as well as control uninfected lysates prepared identically. 
Diluted samples were applied in 100uL volumes to the antigen-coated 96-well plate. Following 
incubation and washing, a horseradish-peroxidase conjugated recombinant protein G from 
Streptococcus sp. was applied for IgG (H+L) detection (Zymed; Thermofisher, Waltham, 
Massachusetts, USA), or specific antiserum for IgG1 or IgG2 detection (Bethyl Laboratories Inc., 
Montgomery, Texas, USA), and the plates incubated. The HRP conjugates were removed by 
washing and a single component 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) 
substrate applied (Kirkgaard & Perry Laboratories, Gaithersburg, Maryland, USA). The enzymatic 
reaction was stopped with 1% SDS (Sigma Aldrich; St. Louis, Missouri, USA). The colour 
changes (which were proportionate to the levels of antibodies) were measured 
spectrophotometrically at 405nm and compared to an immune positive control serum and negative 
control fetal bovine serum concurrently tested on each plate. Units were reported as the percent of 
the optical density (OD) of the positive control serum minus that of the uninfected cell lysate 
(Durham & Sillars, 1986; Ellis et al., 2013; Engvall & Perlmann, 1972).  
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In order to estimate the absolute differences in the magnitude of ELISA unit values, a 
standard curve for each assay was created by serially diluting the positive control serum for each 
antigen (Appendix A). These curves were examined to approximate the change in units that would 
equate to one doubling dilution (twice the amount of antibodies) in the test. A steeper standard 
curve results in a smaller change in units for one doubling dilution, while the converse is true for 
a shallower standard curve where there is a greater change in units equivalent to a doubling 
dilution. For example, for the BRSV (IgG) assay, a change of 10 units is approximately equivalent 
to a doubling dilution (twice the amount of detected antibody), while the much shallower standard 
curve of a PI3V titration results in 30 units equating to a doubling dilution. Doubling dilution 
values for each target were then used to estimate differences between samples for each biologic 
(colostrum, serum and milk) using the following calculation (ELISA units biologic A – ELISA 
units biologic B)/target-specific doubling dilution value.  
Statistical Analysis:  
SPSS version 25 statistical software (SPSS v. 25, IBM, Armonk, New York, USA) was 
used for statistical analysis of ELISA unit values for each assay. A Shapiro-Wilks test revealed the 
ELISA data were not normally distributed, thus the data obtained for the antibodies in the IgG of 
the three biologics (colostrum, serum and milk) were compared using the non-parametric Friedman 
Analysis (ANOVA), with a significance level of P<0.05. Data for paired biologics were compared 




IgG Concentrations in Colostrum, Milk and Serum:  
The concentration of IgG (g/L) from biological samples collected from each animal was 
measured using RID assay as described in the material and methods section. Results from this 
assay showed that colostrum samples had the highest IgG concentration with a mean value of 94.6 
g/L, and showed a wide concentration range from 12.4g/L to 201.7g/L (Table 1). The IgG 
concentration in the milk was much lower (mean value 1.2g/L), but the range was less pronounced, 
spanning from 0.5 to 2.8g/L. Serum samples had mean value of 24.3 g/L and a range from 10.9 
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g/L to 52.1g/L. The total protein, total IgG and Brix scores were consistent with expected ranges 
in post partum dairy animals (Shivley et al., 2018). Table 1 shows the IgG concentrations in the 3 
fluids collected from each of the 24 animals. Though serum values were much higher than those 
of milk, the two biologics mimicked each other in proportion, i.e., if serum IgG was high then milk 
IgG values also tended to be high. This pattern was less consistent in the colostrum, where IgG 
was present in much higher levels than serum or milk. However, in general if IgG in the colostrum 
was very high, the same were true of milk and serum.  
 
Specific Antibody Unit Values in IgG of Colostrum, Milk and Serum of Individual Cows and 
Heifers:  
IgG values in colostrum and CR products are generally reported as g/L, therefore while all 
biologics were normalized to 0.5g/L for testing (to accommodate for low milk values), they were 
mathematically standardized to 1g/L for ease of reporting and discussion purposes.  
Figure 1a and b shows the antigen specific ELISA unit values found in the colostrum, 
serum and milk IgG for the group of animals, for each assay. Appendix B shows the data for each 
individual animal. Antibodies to BRSV (IgG) and BHV1 (IgG) generally followed a similar 
pattern among animals across all three biological fluids (Figure 1a). For these agents, colostrum 
IgG was usually the highest and serum IgG the lowest in antibodies. In general, however, if an 
animal tested high for antibody to these pathogens in the serum IgG, that value was also high in 
the IgG of the colostrum and milk. Colostrum and milk were higher for the IgG1 subclass 
antibodies than the serum, with colostrum higher than milk (Figure 1b). In general, there was 
agreement in the amplitude patterns among the three biological fluids for IgG1 antibodies. Serum 
was always highest in IgG2 antibodies, followed by milk (Figure 1b). These two biologics tended 
to follow the same trend in representation of the IgG2 subclass antibodies, while colostrum did not 
follow the same pattern. In contrast, antibodies to PI3V, another viral pathogen associated with 
respiratory infection, were more variable (Figure 1a). In the majority of animals, antibody values 
were lowest in the serum IgG and highest in the colostrum IgG. Milk IgG antibodies for PI3V 
were more variable and did not follow a consistent pattern, Low values in the serum IgG were not 
always predictive of low values in the milk IgG. 
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Aside from one animal, specific antibodies to S. aureus (IgG) were much higher in the 
serum IgG than in the colostrum IgG, and even more so than in the milk IgG (Figure 1a). In general, 
however, when antibodies to this agent were high in the serum IgG they tended to be high in the 
colostrum IgG. In contrast, antibodies to S. uberis were variable in the IgG in each of the biologics, 
though colostrum IgG often had the highest level of this antibody (Figure 1a). When considering 
IgG1 and 2 subclass antibodies for this pathogen, IgG2 was primarily found in the serum IgG and 
levels of both subclasses fluctuated without an obvious pattern in the IgG of the lacteal fluids 
(Figure 1b). 
E. coli F5 (K99) (IgG) antibodies were most often lowest in the milk IgG and highest in 
the colostrum IgG (Figure 1a). However, within individual animals there was no apparent 
relationship in the E. coli specific antibodies levels in the IgG among the three biologics.  
Rotavirus specific antibodies were consistently highest in the serum IgG, followed by the 
colostrum and then milk IgG (Figure 1a). There were however high levels (relative to the positive 
control) of rotavirus antibodies in the IgG of all three of the biologics from this group of animals. 
Colostrum IgG rotavirus antibodies were primarily composed of IgG1 (Figure 1b). While serum 
rotavirus antibody appeared to be mostly IgG2 (Figure 1b). In individual animals when serum IgG 
rotavirus antibodies were low in IgG1, this subclass was correspondingly high in the colostrum 
IgG. Levels of rotavirus specific IgG1 and IgG2 antibodies were consistently lowest for the milk 
IgG, but when IgG2 was lower in the serum IgG, milk values were higher.  
Bovine coronavirus (IgG) antibodies were most often highest in the colostrum IgG, but 
there was no apparent relationship among the levels in the serum, milk or colostrum IgG of 
individual cows (Figure 1a). However, for BCV (IgG) and rotavirus (IgG), antibodies in the IgG 
of samples from individual cows follow a similar pattern for amplitude (i.e., if antibodies were 
high in the IgG of one biological fluid from that animal, they tended to be high and vice versa), 






Statistical Analysis of Differences in Specific Antibodies in the IgG of Colostrum, Milk and Serum:  
All data was nonparametric by Shapiro-Wilks testing, so statistical analysis via Friedman 
test was employed to determine significance of differences in the levels of specific antibodies in 
the IgG among the three biological samples from this group of 24 cows and heifers. In this test, 
the value of each sample for a given test is given a rank and the squared sum of the ranks compared 
to determine their statistical relationship. There were statistical differences in the antibodies found 
in the IgG from the three biologics for all targets examined except E. coli F5 (K99) and S. uberis 
(IgG1). Further testing by Wilcoxon signed-rank test with Bonferroni correction agreed that there 
were no significant differences among the paired biologics for S. uberis IgG1, however subsequent 
analysis indicated the significance of differences between E. coli F5 (K99) levels in the three 
biologics was likely obfuscated by the scale of some of these differences between pairs of samples 
(Figure 2a-c).  
A Wilcoxon Signed Rank Test, with Bonferroni correction (P<.017) was chosen to 
compare the distributions of the population means of pairs of related biologics (Figure 2). In this 
figure the horizontal axis represents the Z-score of the test. Values to the left of 0 are negative, 
while those to the right are positive. The critical value, or Z-score of this test in a comparison of 
two biologics, with the corrected P-value of 0.017 is +/-2.385. Values greater than 2.385, or less 
than -2.385 denote statistically significant differences between the two biological samples being 
compared.  
Figure 2a compares the mean ELISA antibody units for this group of animals in colostral 
IgG to those in milk IgG. Colostrum IgG is statistically higher in antibodies for most targets tested 
including BRSV (IgG), PI3V (IgG), E. coli F5 (K99) (IgG), S. aureus (IgG), rotavirus (IgG and 
IgG1), and bovine coronavirus (IgG). Additionally, antibodies for BHV1 (IgG), S. uberis (IgG and 
IgG1) and BRSV (IgG1), were higher in the colostrum IgG than milk IgG, but not significantly 
so. Milk IgG was higher in IgG2 antibodies to BRSV, S. uberis IgG1 and rotavirus but not 
statistically so.  
Figure 2b compares mean ELISA antibody units in colostrum IgG to those found in serum 
IgG. Colostrum IgG was statistically higher in specific antibodies to BRSV (IgG and IgG1), BHV-
1 (IgG), PI3V (IgG), E. coli F5 (K99) (IgG), S. uberis (IgG) and Rotavirus (IgG1) and while not 
statistically significant was also higher in antibodies to S. uberis (IgG1) and BCV (IgG). Serum 
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IgG was statistically higher in IgG2 antibodies to all three targets tested (BRSV, S. uberis and 
rotavirus). Serum was also significantly higher in IgG antibodies to S. aureus than the colostrum. 
Figure 2c compares mean ELISA antibody units in serum and milk IgG. The results of this 
analysis were more mixed. In comparison to serum, milk IgG had statistically more antibodies to 
BRSV (IgG and IgG1), BHV-1 (IgG), PI3V (IgG), and rotavirus (IgG1). While not statistically 
significant, milk IgG is also higher in specific antibodies to E. coli F5 (K99) (IgG), and S. uberis 
(IgG and IgG1). The serum IgG contains statistically more antibodies to BRSV (IgG2), S. aureus 
(IgG), S. uberis (IgG2), and rotavirus (IgG and IgG2). Serum IgG is also higher in antibodies to 
BCV than milk IgG.  
 
Assessment of the magnitude of differences in antibodies in IgG in colostrum, milk and serum: 
To consider the potential efficacy of the three bovine IgG sources for passive transfer in 
newborns, the average values of ELISA units for each target antigen were calculated (Table 2).  
To better illustrate the differences between the biologics, the doubling dilution estimates, 
and average ELISA unit values were used to estimate the magnitude of differences among the 
samples to each target and expressed as the magnitude of differences or fold change. For example, 
if the doubling dilution for the BRSV assay was estimated at 10 OD units from the standard curves, 
then the magnitude of the difference between milk and colostrum would be (248 ELISA units-221 
ELISA units)/10 ELISA units ≥ 2-fold magnitude difference (Table 2). 
Colostrum (IgG) antibodies specific to BRSV were 11-fold higher in the colostrum, 
compared to the serum (Table 2). For all other pathogen targets colostrum (IgG) antibodies were 
at least 1-fold higher than serum for all pathogens tested, except BCV, which was nearly identical 
in all three biologics, and S. aureus, which is greater than 8-fold higher in the serum. Colostral 
(IgG) antibodies were 1- to 3-fold higher than the milk for all pathogen targets except BHV-1. 
Magnitude differences between serum and the two lacteal secretions were even more marked for 
some targets, ranging from 1 to 11-fold higher antibody in the lacteals compared to serum. Most 
notably, colostrum and milk IgG providing greater than 8-fold higher antibodies to BRSV in 
comparison to the serum. S. aureus specific antibody was present in substantially higher levels in 
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the serum IgG than IgG of either lacteal secretion, 8-fold greater than colostrum and 13-fold greater 
than milk.  
 Table 2 also shows the calculated estimates of the magnitude of the differences for IgG1 
and IgG2 subclass antibodies for a subset of pathogens. Subclass testing revealed that across all 
three targets, as expected, IgG2 differences were the most dramatic, with serum IgG containing 
much higher levels than IgG in lacteal fluids for BRSV (IgG2) and Rotavirus (IgG2). In particular, 
BRSV (IgG2) specific antibody is 16-fold higher in serum IgG, compared to colostrum IgG and 
14-fold higher in serum IgG compared to milk IgG. In comparison to the other subclass testing, S. 
uberis (IgG2) specific antibodies are not as dramatically different in magnitude in the IgG across 
all three biologics, differing by 3-fold between serum and colostrum IgG and 4-fold between serum 
and milk IgG. 
 
4.4 Discussion  
The results of this study show that colostrum contained higher levels of antibodies per gram 
of IgG to BRSV, S. uberis, E. coli F5 (K99), and rotavirus than serum or milk. As anticipated, 
colostrum and milk IgG was predominately IgG1 subclass (Barrington, Besser, Davis, et al., 1997; 
Staley et al., 1972). Since only the IgG1 subclass antibody is re-secreted at mucosal surface (Besser 
1988, Ellis et al., 2018), this is critical in disease protection in calves early in life.  
Also as expected, serum had higher levels of IgG2 than lacteal samples to all targets tested, 
with the exception of S. uberis specific IgG2 that was highest in the colostrum. Antibodies (IgG) 
to S. aureus were highest in serum IgG. It is likely that this is due to increased IgG2 subclass 
production to this agent and its more abundant representation in the serum (reviewed in, Dego et 
al., 2002). However, in comparison to colostral IgG, serum IgG was much lower in antibodies to 
BRSV (IgG and IgG1), S. uberis (IgG), rotavirus (IgG1) and E. coli F5 (K99) (IgG).  
Milk-derived IgG was lower in magnitude (per gram of IgG) compared to colostrum-
derived IgG for most agents tested in this study. However, Milk IgG was superior to serum IgG, 
providing significantly higher specific antibody to BRSV (IgG and IgG1), S. uberis (IgG and 
IgG1), E. coli F5 (K99) (IgG) and rotavirus (IgG). Additionally, similar to colostrum, milk IgG 
skews toward the IgG1 subclass that is biologically important for the neonate.  
31 
 
The sample size of this study was small, with only 24 animals tested. However, in terms of 
total IgG and farm management practices, they were representative of a standard dairy herd 
Overall, the findings of this study, which was, to the best of our knowledge the first that attempted 
to estimate and compare the specificities of the antibodies sourced from colostrum, milk and 
serum, support the notion that colostrum is the superior source for protective antibodies for 
newborn calves. Nevertheless, our results indicated that milk also had significant levels of IgG1 
immunoglobulins that are critical to protection from a number of ubiquitous calfhood pathogens, 
and could be used to supplement colostrum sourced IgG. However, milk immunoglobulins were 
tested from a single timepoint and are not representative of the entirety of a lactation cycle. As 
well, the number of animals tested in this experiment was small and larger sample size from 




Table 1: Serum total protein (TP) levels and IgG concentration, milk Brix and IgG concentration, 
and colostrum Brix and IgG concentration in 24 post partum dairy cows and heifers.  
 
 
IgG (g/L) TP (g/L) Brix (%) 
N=24 Serum Milk Colostrum Serum Milk Colostrum 
Average 24.3 1.2 94.6 9.2 10.8 23.8 






Figure 1a: ELISA unit values for antigen specific antibodies in IgG (H+L) from colostrum, milk 
and serum for 24 post partum dairy cows and heifers. Range of ELISA values is represented by 
boxes, points represent outliers and error bars represent standard deviation from the mean.
 
Figure 1b. ELISA unit values for antigen specific antibodies in IgG1 and IgG2 subclasses from 
colostrum, milk and serum for 24 post partum dairy cows and heifers. Range of ELISA values is 






Figure 2: Comparison of mean ELISA units for antigen specific antibodies in IgG from colostrum, 
milk and serum in a group of 24 dairy cows and heifers. (Wilcoxon signed rank test with 
Bonferroni correction, P<0.017). Values greater than 2.385, or less than -2.385 (red line) denote 
statistically significant differences between the two biological samples being compared. Unless 




































2c. Mean ELISA antibody unit values in the IgG of serum vs. 
milk
SerumMilk                                                                                                                       
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Table 2. Mean ELISA antibody units in the IgG of the colostrum, milk and serum for each target 
antigen in a group of 24 dairy animals, the number of ELISA units approximately equal to a 
doubling of the amount of antibody and an estimate of the magnitude (doubling) and direction of 
the differences in ELISA units in antibodies in IgG from colostrum, milk and serum*.  
  
Average ELISA units   
Approx. magnitude of 



























BRSV H+L 137 221 248 10 >11 >8 >2 
BRSV IgG1 42 99 115 10 >7 >5 >1 
BRSV IgG2 192 43 28 10 <-16 <-14 <-1 
BHV-1 H+L 124 159 162 15 >2 >2 >0 
PI3V H+L 106 164 201 30 >3 >1 >1 
E. coli F5 
(K99) H+L 
118 120 174 20 >2 >0 >2 
S. aureus H+L 194 62 109 10 <-8 <-13 >4 
S. uberis H+L 163 189 244 25 >3 >1 >2 
S. uberis IgG1 20 23 23 25 >0 >0 >0 
S. uberis IgG2 117 32 31 25 <-3 <-4 <0 
Rotavirus 
H+L 
279 227 268 20 <0 <-2 >2 
Rotavirus 
IgG1 
134 324 398 20 >13 >9 >3 
Rotavirus 
IgG2 
561 298 269 20 <-14 <-13 <-1 
BCV H+L 124 114 141 60 >0 <0 >1 
 
*Values obtained from assessment of serial dilutions of a positive control serum.   
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5. GENERAL DISCUSSION AND CONCLUSIONS: 
Failure of passive transfer of maternal immunoglobulin (FPTI) is the primary factor 
contributing to morbidity and mortality of calves in commercial dairies (Windeyer et al., 2014). 
Commercial colostrum replacer products offer both dairy and beef producers a convenient source 
of nutrition and means to prevent FPTI. This study has examined the IgG in colostrum, milk and 
serum to determine if there are differences in the antibody specificity to better understand if 
immunoglobulin from these sources should be used interchangeably for facilitating passive 
transfer in newborn calves.  
Dairy colostrum is the obvious source of immunoglobulin for CR products but is of limited 
volume and thus expensive and difficult to source. Serum antibodies have been utilized as an 
alternative immunoglobulin source in some countries. However, serum antibodies do not meet 
regulatory requirements in many jurisdictions and while serum can provide high concentrations of 
total Igs, the proportions of antibodies with IgG1 and IgG2 subclass differs from that of colostrum, 
which raises questions around the protective re-secretion properties of about 50% of serum sourced 
immunoglobulin (Besser 1988, Arthington et al., 2002).  
Milk is another readily available source of immunoglobulin for CR products. Like 
colostrum (and unlike serum), milk Ig is primarily IgG1 (reviewed in, Tizard, 2018), critical to 
protection provided by re-secretion at mucosal surfaces (Besser & Osborn, 1993; Ellis et al., 2018). 
However, the specificity of antibodies in milk may differ from colostrum in which the IgG is 
primarily serum derived. While some antibodies in milk are derived via translocation from serum, 
70% of IgG in the milk is produced locally, in the udder (reviewed in, Hurley, 2003). So, while 
the predominant subclass of immunoglobulin in milk and colostrum (IgG1 subclass) the source 
differs and that could affect the spectrum of specificities in each secretion. Thus, it is pertinent to 
understand if the antibody specificities from these lacteal secretions differ significantly.  
Currently, there are no previous studies addressing the question of the specificity of 
immunoglobulins in milk whey (or serum) compared to the IgG in colostrum. A more complete 
understanding of the antibody specificity could influence their use and potentially lead to improved 
CR products and improved calf health and performance outcomes.  
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A prerequisite for this study was a reliable means to quantify the levels of antibodies 
recognizing the target antigens. The qualitative ELISA is primarily an indicator of the presence, 
or absence of a target. At best, it is an ordinal measure of antibody concentration (Tyler & Cullor, 
1989). In a qualitative indirect ELISA, positive samples may need to be diluted by many orders of 
magnitude before the magnitude of the value changes to demonstrate differences in antibody level 
between samples in the same test. Generally speaking, the qualitative ELISA can only give an 
indication of “high”, “medium” and “low” levels of antibody. This is because the samples are read 
at a single dilution and compared to a positive control that has been titrated to determine the 
standard curve for the assay (Durham & Sillars, 1986; Graham et al., 1998). The positive control 
is read at the top of the linear portion of the standard curve, and the sample dilutions ideally fall 
within the linear portion of this curve. For the purposes of this study, it was important to compare 
the amount of each specific antibody per gram of IgG directly between the serum, milk, and 
colostrum samples more precisely. Thus, there was a need to modify the existing ELISAs for 
increased precision. As shown in Table 1 the samples tested varied by up to 100X in IgG 
concentration. To improve precision, the IgG was adjusted to the same concentration for all 
samples to help ensure that the values fell within the linear range of the standard curve. In addition, 
for many of the assays used in this study, the slope of the standard curve was very shallow, and 
varied among target antigens making it difficult to understand how differences in units related to 
actual differences in magnitude of specific antibodies (Appendix A). That is, a steeper standard 
curve results in a smaller OD change resulting from one doubling dilution (a doubling dilution is 
a change of antibodies of one-fold), while the converse is true for a shallower standard curve where 
there was a greater change in OD equivalent to a doubling dilution. For example, for the BRSV 
(H+L) assay, a change in OD of 10 units is approximately equivalent to a doubling dilution, while 
the much shallower standard curve of a PI3 titration results in 30 OD units for a doubling dilution. 
Therefore, a doubling dilution (which is a fold difference in antibodies) was not equivalent to 
double the units. We attempted to account for the slope of the standard curves by estimating the 
magnitude of change of units that would equate to one doubling dilution of the antibodies in the 
assay (Table 2) and thus enable an estimate of the fold differences in antibodies among samples.  
We tested serum, milk and colostrum of 24 dairy cattle from a single dairy farm in New 
York State for antibody specificities to the IgG of eight common pathogens of dairy cattle involved 
in either mastitis (S. aureus and S. uberis), NCD (BCV, rotavirus, E. coli F5 (K99)) or BRD (PI3, 
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BRSV, BHV-1, BCV). We further tested the IgG1 and 2 subclasses antibodies for one pathogen 
from each category (BRSV, S. uberis, rotavirus). The results of the specific antigen ELISAs on 
individual animals show a high degree of variability between each biologic for each target 
(Appendix B), even when all samples are tested at the same standardized total IgG value. While 
the strategy described previously allowed a comparison of the amounts of antibodies in different 
samples within each assay there was no means to compare between different assays. Many factors 
such as natural variations in the binding affinity and avidity of the antigen-antibody complex, 
antigenicity of agent and natural changes in cell culture can affect the sample dilution selected, as 
well as the slope and range of the standard curve. Physiological differences in individual cows and 
even environmental exposures and vaccination composition can influence background binding of 
each assay. Thus, the values obtained in an IgG normalized, semi-quantitative ELISA for BRSV 
using colostrum can be compared to the numbers obtained from testing serum or milk from this or 
other animals but cannot be compared to an assay for another target, such as rotavirus in either this 
or other animals.  
We also tested for specific antibodies to the same pathogens in the IgG of forty-one 
commercially available products. These data are presented in Appendix C. For some products 
(n=12) it was not possible to discern the source of the IgG, for others the products appeared to be 
formulas with “mixed” IgG sourced from serum as well as either colostrum or whey (n=7). The 
results of testing the products of known Ig source, overall, support the findings of the study of the 
individual animal testing. Even without consideration of the differences in IgG subtypes, milk and 
colostrum Ig based products were more similar in most specific antibodies than products sourced 
from serum.  
 
Limitations of the study and future directions: 
The sample size of this study was small, with only 24 animals tested. However, in terms of 
total IgG and farm management practices, they were representative of a standard dairy herd. To 
add statistical weight to the testing in this study, it would be beneficial to apply the methodology 
used here to test serum, milk and colostrum samples from a much larger group of more 
geographically distributed animals. As well, the milk samples tested were sampled at a single 
timepoint and are not representative of the Ig profile over the entire lactation cycle. In addition, 
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there is merit to testing the commercially available colostrum products to determine the differences 
in specific antibodies among products. In the current study a variety of products, mainly from the 
US market (as Canada has only colostrum-based products) were tested and these data are shown 
in Appendix C. A significant limitation to these data is that most products sold in US markets are 
unlicensed and therefore ingredients are unknown. 
Indirect ELISAs, even with the modifications used in this study are not precisely 
quantitative and therefore the data is only an estimate of the differences in levels of specific 
antibodies. More precise assays would be desirable but are not currently readily available. 
Additionally, the indirect ELISA, demonstrates antibodies binding to the infectious agent, and 
those antibodies may bind portions of the agent that are not essential for viral invasion of host 
cells, and/or other means of pathogenic effects, i.e., these ELISAs are a measure of many protein 
epitopes, both neutralizing and non-neutralizing, and not necessarily an indication of the presence 
or scale of pathogen neutralizing antibody. Antibody levels are not necessarily predictive of 
disease (sometimes calves with high Ab levels experience morbidity, sometimes calves with low 
antibody levels appear protected). Purification of ELISA antigens to create targets to highly 
immunogenic proteins receptors may provide more robust answers regarding the nature of specific 
immunoglobulins to each target agent, while broadening the range of the standard curve and giving 
us more comparative strength in regard to the antibody levels at the high and low end of these 
assays.  
Feeding trials in newborn calves are the ultimate means to test the efficacy of these 
products. Trials comparing colostral and serum based CR products have had variable success 
(reviewed in, Cabral et al., 2013; reviewed in, Godden & James, 2020) leading to questions around 
the effects of processing colostral and serum antibodies on functionality and absorptive 
efficiencies. While the specific antibody profile of milk closely resembles that of colostrum, the 
magnitude of antibody in this biologic both in terms of overall IgG concentration and of specific 
antibodies of relevance per gram of IgG is significantly lower. Additionally, if milk whey used for 
CR production is collected from cheese production waste, it must be considered that this byproduct 
has undergone additional processing (e.g., rennet addition) and pasteurization without 
consideration for the need to preserve antibody functionality, so additional testing and 
modifications would need to be considered and tested. So while milk-derived IgG appears to have 
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utility, whey-derived products should be tested in controlled feeding trials for functionality and 
absorptive efficiencies in comparison to maternal colostrum and commercial counterparts.  
Testing of the currently available colostrum replacer products was limited by difficulties 
in accessing information about the source of the IgG in many of the products. In Veterinary 
Biologics licensed products the source is colostrum however there is no means to know the source 
in unlicensed products, which are the vast majority available commercially. This is further 
complicated in that the Ig in many unlicensed products changes with time and cost of obtaining 
IgG from different sources.  
 
Conclusions: 
Colostrum ingestion and the resultant passive transfer of specific antibodies is a 
prerequisite for calf health. Colostrum replacement products have a role in ensuring optimal 
passive transfer management. Understanding of composition and efficacy of CR product IgG will 
lead to better quality products able to inform management decisions around calf health and lead to 
better disease management outcomes.  
Serum-based products are not currently used in Canada, but regulations in many other 
countries including the USA allow commercial CR products comprised in whole or in part of 
bovine-serum Igs. In this small group of animals, compared to colostrum, serum appears to provide 
increased levels of antibodies (per gram of IgG) to S. aureus and if additional agents are tested 
may prove to have other, targeted benefit over the lacteal biologics to specific pathogens. However, 
overall, serum IgG has lower levels of antibodies to most pathogens of importance for newborn 
calves and the benefit of serum Igs for CR products further is reduced by the large amount of IgG2 
subclass present (about 50%), diminishing the magnitude of protective re-secretion at mucosal 
surfaces of the calves (Besser 1988, Ellis 2019).  
The results of this study indicate that milk sourced IgG is a more promising ingredient to 
supplement the scarce supply of Ig available from colostrum for day one use for passive transfer. 
In contrast to serum-based IgG the antibodies found in milk are more similar in specificity (per 
gram of IgG) and subclass distribution (predominately IgG1) to those found in colostrum.  
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In conclusion, the results of this study suggest that, when directly comparing serum, milk and 
colostrum IgG for the antibodies to target pathogens, colostrum is the best source of 
immunoglobulin to use in colostrum replacer products. However, given the similar antibody 
subtype profile and specificity of milk immunoglobulin, harvesting, purifying and concentrating 
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A. Titrations of Positive Control Serum to Determine ELISA-Target Specific Magnitude 
Changes in ELISA Units.  
A. 1.  Two-fold serial dilution of BRSV positive control serum tested in an indirect ELISA to 
determine magnitude of optical density unit change that equates to one doubling dilution of the 








A.2.  Two-fold serial dilution of PI3V positive control serum tested in an indirect ELISA to 
determine the magnitude of optical density units change that equates to one doubling dilution in 






B. Individual Cow or Heifer Specific Antibody ELISA Units 
ELISA unit values for antigen specific antibodies in IgG from colostrum, milk and serum (a-n) for 
24 post partum dairy cows and heifers.  
B.1.  BRSV specific IgG (H&L) ELISA antibody units in the IgG of serum, milk and colostrum 






B.2.  BRSV specific IgG (IgG1) ELISA antibody units in the IgG of serum, milk and colostrum 
for 24 post partum dairy cows and heifers. 
 
 
B.3. BRSV specific IgG (IgG2) ELISA antibody units in the IgG of serum, milk and colostrum 





B.4. BHV-1 specific IgG (H&L) ELISA antibody units in the IgG of serum, milk and colostrum 
for 24 post partum dairy cows and heifers. 
 
 
B.5. PI3V specific IgG (H&L) ELISA antibody units in the IgG of serum, milk and colostrum 







B.6. S. aureus specific IgG (H&L) ELISA antibody units in the IgG of serum, milk and 
colostrum for 24 post partum dairy cows and heifers. 
 
 
B.7. S. uberis specific IgG (H&L) ELISA antibody units in the IgG of serum, milk and 






B.8. S. uberis specific IgG (IgG1) ELISA antibody units in the serum, milk and colostrum for 
24 post partum dairy cows and heifers. 
 
 
B.9. S. uberis specific IgG (IgG2) ELISA antibody units in the serum, milk and colostrum for 





B.10. E. coli F5 (K99) specific IgG (H&L) ELISA antibody units in the IgG of serum, milk and 
colostrum for 24 post partum dairy cows and heifers. 
 
 
B.11. Rotavirus specific IgG (H&L) ELISA antibody units in the IgG of serum, milk and 






B.12. Rotavirus specific IgG (IgG1) ELISA antibody units in the serum, milk and colostrum for 
24 post partum dairy cows and heifers. 
 
 
B.13. Rotavirus specific IgG (IgG2) ELISA antibody units in the serum, milk and colostrum for 






B.14. BCV specific IgG (H&L) ELISA antibody units in the IgG of colostrum, milk and serum 




C. Commercial Colostrum Replacer Product Testing 
An attempt was made to assess differences among the specific antibodies present in 
commercially available colostrum replacer and feed products. Forty-one CR products were 
purchased from feed stores in North America. When possible, products were divided into groups 
based on their stated Ig source (see Appendix C). Products were reconstituted according to package 
directions. Similar to the testing protocol for samples from the cows and heifers used in this study, 
products were first tested for total IgG concentration via RID. This value was used to dilute each 
product to 0.5 g/L for specific target ELISA testing. As with the biologic sample testing, samples 
of these products were then further diluted, to working dilutions such that the values were expected 
to be within the linear portion of each of the ELISA standard curves. The values were normalized 
post-testing to reflect specific antibody amount per 1g/L total IgG. Product testing ELISAs were 
performed for IgG H+L only. 
As shown in Appendix C, product testing revealed highly variable levels of specific 
antibodies in the IgG among products. Even within the products that claim to source Igs from 
maternal colostrum, total IgG was not indicative of levels of specific antibody per gram of IgG 
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across the targets tested. Many products, regardless of Ig source, had IgG with low specific 
antibodies to both PI3V and E. coli F5 (K99).  
However, similar to the animal testing performed for this study, colostrum-derived product 
IgG generally were the highest in terms of levels of specific antibodies. These products were the 
highest of the other single-Ig-sourced products for BRSV, BHV-1 and PI3V specific antibodies 
and the other targets tested were generally high for specific antibodies in the colostrum CR 
products. Serum-based product IgG was lower in specific antibodies to BRSV, BHV-1 and PI3 
than the milk and colostrum-derived products and highest for specific antibodies in S. aureus, S. 
uberis, and rotavirus (Appendix B & C). CR products made from milk whey would likely represent 
a broader spectrum of the lactation cycle while this study chose to analyze samples from a single 
timepoint (day 5). Despite being collected at a single timepoint, milk or whey-based product IgG 
was higher than serum IgG for BRSV, PI3V and BHV-1, and were generally comparable to the 
colostrum in regard to levels of the other targets tested. 
The IgG in both colostrum and milk-derived products was statistically higher than the 
serum IgG in specific antibodies to BRSV (Appendix B & C). Products claiming mixed sources 
of Igs, or for which the Ig source was unclear, tended to have variable levels of specific antibodies 
across the pathogen target panel used in this study, with most testing low for antibodies to BRSV, 
BHV-1, PI3V and E. coli F5 (K99).  
In general, this product testing supports the findings of the animal testing in this study and 
indicates that colostrum-based IgG tends to have the highest coverage in terms of antibody 
specificities. Milk/whey-sourced IgG appears to provide comparable amounts of specific 
antibodies to the colostrum-derived CR formulas, and serum- based products tend to provide more 
specific antibody to bacterial pathogens. There were, however, differences in the serum IgG in 
products from tests of the individual animals IgG to some agents. It may be pertinent that post 
partum dams have transferred much of their serum IgG1 to the colostrum while blood-base 
products are from slaughter animals which may have a different profile of specific IgG. 
Higher total IgG products (presumably higher quality products) are comprised of IgG with 
broad-spectrum antibody populations to environmentally relevant pathogens of bovid neonates, 
but high total IgG is not a guarantee that CR formulas will provide greater specific antibody to any 
one particular target, suggesting the necessity of understanding the antibody specificities of 
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products and their immune components. In all products, antibodies specific to the IgG of bacterial 
pathogens tends to be highest, which may be responsible for inflating the total IgG of lesser quality 
products. A better understanding of specific antibodies in CR products is one critical aspect to 
understanding why results of CR feed trials are variable
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C.1. ELISA antibody units in the IgG of colostrum replacer products (CR). Products are grouped by immunoglobulin source. (All 
samples were tested at 0.5g/L total IgG and normalized to 1g/L total IgG for ELISA testing.)  
 
(n=12) (n=7) (n=9) (n=9) (n=4) 
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C.2.  Kruskal Wallis test with Dunn post-hoc analysis comparing specific antibodies in single-
source commercial colostrum replacer products 
ELISA Target Kruskal-Wallis Test Paired Treatments Dunn Post Hoc Test 
Total IgG 0.123 
Serum vs. Milk *  
Serum vs. Colostrum *  
Milk vs. Colostrum *  
BRSV 0.010 
Serum vs. Milk 0.046 
Serum vs. Colostrum 0.003 
Milk vs. Colostrum 0.191 
BHV-1 0.151 
Serum vs. Milk *  
Serum vs. Colostrum *  
Milk vs. Colostrum *  
PI3V 0.461 
Serum vs. Milk *  
Serum vs. Colostrum *  
Milk vs. Colostrum *  
E. coli F5 (K99) 0.666 
Serum vs. Milk *  
Serum vs. Colostrum *  
Milk vs. Colostrum *  
S. aureus 0.014 
Serum vs. Milk 0.716 
Serum vs. Colostrum 0.005 
Milk vs. Colostrum 0.012 
S. uberis 0.050 
Serum vs. Milk 0.293 
Serum vs. Colostrum 0.014 
Milk vs. Colostrum 0.105 
rotavirus 0.034 
Serum vs. Milk 0.637 
Serum vs. Colostrum 0.011 
Milk vs. Colostrum 0.030 
BCV 0.193 
Serum vs. Milk *  
Serum vs. Colostrum *  
Milk vs. Colostrum *  
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A Kruskal-Wallis analysis was performed on ELISA ODs of single-source colostrum replacer 
products as a global test for differences in specific antibodies to the H+L of BRSV, BHV-1, PI3V, 
E. coli F5 (K99), S. aureus, S. uberis, rotavirus and BCV among IgG sourced from serum, milk 
and colostrum (P<.05). When differences between two biologics were significant, a post hoc 
analysis using the Dunn test was employed (P<.05).  
* Represent test values that did not meet the level of significance for this statistical test. For 
comparisons where the Kruskal-Wallis test did not meet the level of significance, post hoc tests 
were not completed.  
